1,385.00
+0.87%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dr Reddy's Laboratories Ltd
Its shares trade on NSE under the ticker DRREDDY.NS. It has been listed since 1 January 1986. It is a member of the Nifty 50. In the fiscal year to 31 March 2026, it reported revenue of ₹335.93bn and net income of ₹42.85bn. At that date it held total assets of ₹579.35bn and shareholders' equity of ₹377.06bn.
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The firm operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jan 1986
- Employees
- 21,650
- Website
- drreddys.com ↗
Leadership
Pay as last reported
- Mr. Kallam ReddyExecutive Chairman of the Board, since 2022₹118.2m
- Mr. Gunupati PrasadExecutive Co-Chairman, Managing Director, since 2001₹188.3m
- Mr. Erez IsraeliChief Executive Officer₹141.6m
- Mr. Mannam NarasimhamChief Financial Officer, since 2024
- Mr. Patrick AghanianChief Executive Officer, European Generics₹76.8m
- Mr. M. RamanaChief Executive Officer, Branded Markets (India and Emerging Markets)₹64.8m
- Mr. Deepak SapraChief Executive Officer - API and Services₹35.1m
- Mr. Phanimitra BChief Digital and Information Officer
- Mr. K. SinghCompliance Officer, Company Secretary, Head - CSR₹2.2m
- Mr. Sushrut KulkarniGlobal Head - Integrated Product Development Organisation
- Mr. Sanjay SharmaHead - Global Operations₹43.6m
- Mr. Leo PuriLead Non-Executive Independent Director₹20.1m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 83
- Environment
- 77
- Social
- 84
- Governance
- 89
- Direct emissions (scope 1)
- 189,530 t
- Energy emissions (scope 2)
- 114,655 t
- Value chain emissions (scope 3)
- 866,993 t
- Women in the workforce
- 19.499%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Hyderabad, Telangana
- Employs 21,650 full-time employees
- Operates in three segments: Global Generics, PSAI, and Proprietary Products
Weaknesses
- No specific weaknesses mentioned in the provided information
- No financial data provided for analysis
- No market share or competitive position details
Opportunities
- Expansion in Global Generics segment for prescription and OTC products
- Growth potential in PSAI segment for active pharmaceutical ingredients
- Development of new chemical entities in Proprietary Products segment
Threats
- No specific threats mentioned in the provided information
- No competitive landscape details provided
- No regulatory or market risks identified
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.